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(EART FAILURE CAUSES MORBIDITY AND MORTALITY 
#ELL  TRANSPLANTATION  USING  SKELETAL  MUSCLE MYO
BLAST IS PROMISING FOR MYOCARDIAL REPAIR AS IT CAN 
REGENERATE  AND  REPAIR  THE  INJURY  3KELETAL  MYO
BLASTS ARE UNIPOTENT PROGENITOR CELLS  THAT CAN BE 
EXPANDED AND GENETICALLY MODIFIED TO DELIVER AN
GIOGENIC CYTOKINES AND GROWTH FACTORS TO ENCOUR
AGE  ANGIOMYOGENESIS  -YOBLAST  TRANSPLANTATION 
INHIBITS  VENTRICULAR  REMODELLING  DECREASES  LEFT 
VENTRICULAR  DIASTOLIC  DIMENSION  INCREASES  MYO
CARDIAL WALL THICKNESS AND MINIMIZES GLOBAL VEN
TRICULAR DILATATION IN ANIMALS /NGOING TRIALS WITH 
SKELETAL MYOBLAST TRANSPLANTATION SHOW IMPROVE
MENT  IN  PERFUSION  AND  METABOLIC  ACTIVITY  4IME 
CONSTRAINTS  AND  THE  PROBLEM  OF  GENERATING  AU
TOLOGOUS SKELETAL MYOBLASTS FOR EVERY PATIENT CAN 
BE OVERCOME IF ALLOGENEIC SKELETAL MYOBLASTS FROM 
HEALTHY  YOUNG  DONORS  CAN  BE  MADE  AVAILABLE 
-YOBLAST  TRANSPLANTATION  IS  CONFRONTED WITH  THE 
PROBLEM OF DONOR CELL  SURVIVAL POSTTRANSPLANTA
TION  )TS  SAFETY  AND  FEASIBILITY  HAVE  BEEN  DOCU
MENTED  DURING  ANIMAL  AND  PHASE  )  STUDIES 4HE 
ONLY  SERIOUS POSTOPERATIVE  ADVERSE  EVENT  RELATED 
TO  THE  PROCEDURE  WAS  VENTRICULAR  ARRHYTHMIAS 
4HE  RESULTS  OF  PHASE  )  STUDIES  ARE  STILL  PRELIMI
NARY %NDPOINT MEASUREMENTS HIGHLIGHT IMPROVE
MENT  IN  QUALITY  OF  LIFE  REDUCED  NITROGLYCERINE 
CONSUMPTION  ENHANCED  EXERCISE  TOLERANCE  IM
PROVEMENT  IN  .9(!  #LASS  AND  WALL  MOTION  BY 
ECHOCARDIOGRAPHY AND SIGNIFICANTLY REDUCED PER
FUSION DEFECTS &UTURE DIRECTIONS INCLUDE CONCERT
ED  COLLABORATIVE  EFFORTS  STRICT  INCLUSION  AND  EX
CLUSION  CRITERIA  BETTER  ESTABLISHMENT  OF  TARGET 
4RASPLANTE DE MIOBLASTOS EN LA INSUFICIENCIA CARDÓACA 
n DEL LABORATORIO A LA CLÓNICA
,A  INSUFICIENCIA  CARDÓACA  ES  CAUSA  DE MORBI
MORTALIDAD %L TRASPLANTE CELULAR CON MIOBLASTOS 
DE MÞSCULO ESQUELÏTICO ES PROMETEDOR EN LA REPA
RACIØN  MIOCÈRDICA  YA  QUE  PUEDE  REGENERAR  LA 
ZONA  AGREDIDA  ,OS  MIOBLASTOS  ESQUELÏTICOS  SON 
CÏLULAS  PROGENITORAS  UNIPOTENCIALES  QUE  PUEDEN 
SER MODIFICADAS GENÏTICAMENTE PARA LIBERAR CITO
CINAS ANGIOGÏNICAS Y FACTORES DE CRECIMIENTO PARA 
FAVORECER  LA  ANGIOMIOGÏNESIS  %L  TRASPLANTE  DE 
MIOBLASTOS  INHIBE  LA  REMODELACIØN  VENTRICULAR 
DISMINUYE EL DIÈMETRO  TELEDIASTØLICO AUMENTA EL 
GROSOR DE  LA PARED VENTRICULAR Y MINIMIZA  LA DI
LATACIØN VENTRICULAR EN ANIMALES ,OS ENSAYOS EN 
MARCHA MUESTRAN MEJORÓA DE LA PERFUSIØN Y ACTI
VIDAD METABØLICA %L PROBLEMA DE  LA  GENERACIØN 
DE MIOBLASTOS  ANTØLOGOS  PARA  CADA  PACIENTE  PO
DRÓA  SOLUCIONARSE  SI  SE  DISPUSIESE  DE  MIOBLASTOS 
ALOGÏNICOS  DE  DONANTES  JØVENES  SANOS  %L  TRAS
PLANTE DE MIOBLASTOS  TIENE EL PROBLEMA DE  LA  SU
PERVIVENCIA CELULAR POSTRASPLANTE 3U FACTIBILIDAD 
Y SEGURIDAD SE HAN DOCUMENTADO EN ESTUDIOS ANI
MALES Y DE FASE ) %L ÞNICO EVENTO ADVERSO POSTO
PERATORIO  RELACIONADO  HA  SIDO  LAS  ARRITMIAS 
VENTRICULARES ,OS RESULTADOS DE ESTUDIOS EN FASE ) 
SON PRELIMINARES ,AS MEDICIONES DE PUNTOS FINA
LES CONFIRMAN UNA MEJORÓA EN LA CALIDAD DE VIDA 
REDUCCIØN DEL CONSUMO DE NITROGLICERINA AUMEN
TO  DE  LA  CAPACIDAD  DE  EJERCICIO  MEJORÓA  DE  LA 
CLASE  FUNCIONAL  .9(!  Y  MOTILIDAD  PARIETAL  POR 
ECOCARDIOGRAFÓA  Y  REDUCCIØN  DE  LOS  DEFECTOS  DE 
#ORRESPONDENCIA 
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(EART FAILURE IS THE LEADING CAUSE OF MORBIDITY AND MOR
TALITY IN DEVELOPED COUNTRIES )N THE 5NITED 3TATES IT AFFECTS 
NEARLY    MILLION  PEOPLE  AND  WITH    NEW  PATIENTS 
ADDED TO THE LIST EVERY YEAR #URRENT TREATMENT MODALITIES ARE 
INADEQUATE %VEN WITH BEST MEDICAL MANAGEMENT THE MORTAL
ITY FOR END STAGE CARDIAC FAILURE IS EXTREMELY HIGH AND HEART 
TRANSPLANTATION IS NOT A FEASIBLE OPTION FOR MOST
!S  CARDIOMYOCYTES  RETAIN  LITTLE  ABILITY  TO  REGENERATE  OR 
REPLACE  DAMAGED  CELLS  CELL  TRANSPLANTATION  USING  SKELETAL 
MUSCLE MYOBLAST IS A PROMISING ALTERNATIVE THERAPY FOR MYO
CARDIAL REPAIR 4HIS NOVEL APPROACH SEEKS TO COMPENSATE FOR 
THE  EXTENSIVE  LOSS  IN  CARDIOMYOCYTES  WHICH  IS  IN  TURN  A 
CONSEQUENCE OF  LEFT VENTRICULAR DYSFUNCTION  )N  THIS  REVIEW 
WE LOOK AT THE OVERWHELMING EVIDENCE TO SUPPORT THIS NEW 
AND NOVEL APPROACH IN THE TREATMENT OF HEART FAILURE
3KELETAL MUSCLE UNLIKE CARDIAC MUSCLE	 HAS THE ABIL
ITY TO REGENERATE AND REPAIR THE INJURY DUE TO THE PRESENCE 
OF MYOBLASTS 4HEY PROLIFERATE AND DIFFERENTIATE WHEN AC
TIVATED  IN  RESPONSE  TO MUSCLE  INJURY 3KELETAL MYOBLASTS 
ARE MONONUCLEATED UNIPOTENT PROGENITOR CELLS THAT CAN BE 
EXPANDED IN VITRO 3KELETAL MYOBLASTS CAN BE GENETICALLY 
MODIFIED  IN  VITRO  TO  DELIVER  ANGIOGENIC  CYTOKINES  AND 
GROWTH  FACTORS  TO  ENCOURAGE  ANGIOMYOGENESIS  !NIMAL 
STUDIES HAVE SHOWN THAT GRAFTED MYOBLASTS FORM MYOTUBES 
IN  THE  MYOCARDIUM  AND  EVENTUALLY  MATURE  TO  BECOME 
WELLFORMED MYOFIBERS WITH CONTRACTILE APPARATUS 
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+AO  FIRST  DEMONSTRATED  THE  FEASIBILITY  OF  SKELETAL 
MYOBLAST  TRANSPLANTATION  FOR CARDIAC  REPAIR -YOBLASTS 
WERE  INJECTED  INTO  THE  CENTER  OF  SCAR  USING  CRYOINJURED 
MYOCARDIAL MODEL (ISTOLOGICAL STUDY DEMONSTRATED VI
ABLE MYOFIBERS  IN  SCAR  TISSUE  )N  THE  SUBSEQUENT  YEARS 
MANY RESEARCHES WERE ABLE TO REPEAT THESE FINDINGS USING 
DIFFERENT  ANIMAL MODELS OF HEART  FAILURE !  LANDMARK 
STUDY BY 4AYLOR ET AL 	 DEMONSTRATED THE EFFECTIVE
NESS  OF  SKELETAL  MYOBLAST  TRANSPLANTATION  FOR  IMPROVE
MENT  OF  CARDIAC  FUNCTION  IN  RABBIT  HEART  MODEL  OF 
CRYOINJURY &URTHERMORE SKELETAL MYOBLAST TRANSPLANTA
TION IMPROVED DIASTOLIC COMPLIANCE PRIOR TO SYSTOLIC PER
FORMANCE 4HE IMPROVED DIASTOLIC FUNCTION WAS RELATED 
TO INCREASED REGIONAL STRAIN DECREASED DYNAMIC STIFFNESS 
UNAFFECTED  STATIC  STIFFNESS  AND  REVERSED  DIASTOLIC  CREEP 
"OTH TO REGIONAL AND VENTRICULAR SYSTOLIC FUNCTION CAN BE 
IMPROVED BY MYOBLAST TRANSPLANTATION
-YOBLAST TRANSPLANTATION DELIMITS OR INHIBITS VENTRICU
LAR  REMODELLING -YOBLAST  TRANSPLANTATION  DECREASES  LEFT 
VENTRICULAR DIASTOLIC DIMENSION INCREASES MYOCARDIAL WALL 
THICKNESS AND MINIMIZE GLOBAL VENTRICULAR DILATATION 
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4HE  FIRST  CLINICAL  APPLICATION OF  CELL  TRANSPLANTATION AS 
AN ADJUNCT TO CORONARY ARTERY BYPASS GRAFTING #!"'	 WAS 
PERFORMED BY -ENASCHÏ ET AL USING CULTURED AUTOLOGOUS 
SKELETAL MYOBLASTS  IN A YEAROLD MALE PATIENT 4HE PA
TIENT WAS  IN .EW 9ORK (EART !SSOCIATION  .9(!	 #LASS 
))) WITH A MEAN ,6%& OF    BY ECHOCARDIOGRAPHY 
&OLLOWUP AT  MONTHS SHOWED THE PATIENT WAS IN .9(! 
#LASS )) WITH AN IMPROVEMENT IN THE ,6%& TO  
-ENASCHÏ ET AL HAVE ALSO REPORTED NINE MORE PA
TIENTS AS A PART OF PHASE ) TRIALS 4HE PATIENTS MEAN AGE 
   YEARS	 WERE DIAGNOSED WITH SEVERE LEFT VENTRICU
LAR DYSFUNCTION ,6%&  	 !N AVERAGE OF  X  
AUTOLOGOUS  MYOBLASTS  WAS  INJECTED  INTO  AKINETIC  NON
REVASCULARIZABLE AND NONVIABLE SCAR AS ASSESSED BY DO
BUTAMINE  ECHOCARDIOGRAPHY  AND  POSITRON  EMISSION 

PERFUSIØN &UTURAS DIRECCIONES INCLUYEN ESFUERZOS 
COLABORATIVOS  CRITERIOS  DE  INCLUSIØN  Y  EXCLUSIØN 
ESTRICTOS Y MEJOR CARACTERIZACIØN DE LA POBLACIØN 
DIANA  3E  NECESITA  TRABAJAR MÈS  EN  EL  TIPO  IDEAL 
DE  CÏLULA  NÞMERO  ØPTIMO  DE  CÏLULAS  Y  RUTA  DE 
ADMINISTRACIØN 3E ESTÈN ESTUDIANDO EL MOMENTO 
IDEAL DEL TRASPLANTE Y EL MODO DE LIBERACIØN CELU
LAR %L USO DE TÏCNICAS CELULARES PARA LA REGENERA
CIØN CARDÓACA ES PROMETEDOR EN EL TRATAMIENTO DE 
LA INSUFICIENCIA CARDÓACA 
0ALABRAS CLAVE )NSUFICIENCIA CARDÓACA -IOBLASTO 
ESQUELÏTICO 4RASPLANTE CELULAR !NGIOMIOGÏNESIS
POPULATION &URTHER WORK NEEDS TO BE DONE ON THE 
IDEAL CELL TYPE OPTIMAL NUMBER OF CELLS AND ROUTE 
OF ADMINISTRATION 4HE MOST SUITABLE TIME FOR CELL 
TRANSPLANTATION AFTER ISCHEMIC INJURY AND OPTIMAL 
MODE  OF  CELL  DELIVERY  ARE  EVALUATED  4HE  USE  OF 
CELLBASED TECHNIQUES TO ASSIST WITH CARDIAC REGEN
ERATION HOLDS PROMISE FOR THE TREATMENT OF HEART 
FAILURE 
+EY  WORDS  (EART  FAILURE  3KELETAL  MYOBLASTS 
#ELL TRANSPLANTATION !NGIOMYOGENESIS
  %UGENE +7 3IM ET AL -YOBLAST TRANSPLANTATION FOR HEART FAILURE n &ROM BENCH TO BEDSIDE
TOMOGRAPHY  0%4	  4HE  CELL  TRANSPLANTATION  PROCEDURE 
WAS EVENTFREE WITHOUT ANY PERIOPERATIVE COMPLICATIONS 
4HE NINE OPERATIVE  SURVIVORS WERE  FOLLOWED  FOR  UP  TO 
 MONTHS 4HE RESULTS SHOWED AN IMPROVEMENT IN .9(! 
#LASS FOR ALL THE PATIENTS FROM .9(! #LASS    TO 
      P    	  IN  PARALLEL WITH  DOCUMENTED  IM
PROVEMENT IN ,6%& FROM    TO    P  	 
#HACHQUES ET AL  INITIATED A PHASE ) STUDY FOR AUTOLO
GOUS  MYOBLAST  TRANSPLANTATION  AS  AN  ADJUNCT  TO  ROUTE 
#!"'  IN   MALE  AND    FEMALE  PATIENT  IN .9(!  FUNC
TIONAL #LASS ))) 4HE STUDY HAS BEEN EXTENDED TO INCLUDE 
 PATIENTS  MALE	 WITH AN AVERAGE .9(! #LASS  
4HE  PATIENTS  WERE  DIAGNOSED  WITH  IMPAIRED  LEFT  VEN
TRICULAR FUNCTION ,6%&    	 AND LEFT VENTRICULAR 
POSTERIOR WALL POSTISCHEMIC SCARS AKINETIC AND ABSENCE 
OF METABOLIC VIABILITY	 4HE PROPAGATION OF THE CELLS WAS 
CARRIED  OUT  IN  COMPLETE  HUMAN MEDIUM  USING  THE  PA
TIENTS OWN SERA 4HERE WERE NO COMPLICATIONS RELATED TO 
THE CELL TRANSPLANTATION PROCEDURE 4HE PATIENTS SHOWED 
UNEVENTFUL RECOVERY AND WERE DISCHARGED FROM THE )#5 
  DAYS  AFTER  SURGERY .O  CARDIAC  ARRHYTHMIAS WERE  OB
SERVED AT  FOLLOWUP MEAN    MONTHS	 %CHOCARDIO
GRAPHIC STUDIES SHOWED AN IMPROVEMENT IN REGIONAL WALL 
MOTION  FROM  AKINETIC  CARDIOMYOPATHY  TO  HYPOKINETIC 
VENTRICULAR  WALL	  4HE  INFARCT  SCAR  SIZE  APPEARED  TO  BE 
SIGNIFICANTLY REDUCED FROM    TO    CM P  	 
-YOCARDIAL  VIABILITY  TESTS  SHOWED  REGENERATING  NODES 
WITH  PATIENTS  MOVING  FROM  HEART  FAILURE  #LASS    TO 
#LASS  
-YOBLAST TRANSPLANTATION AS HAS ALSO BEEN CARRIED OUT 
IN  ASSOCIATION  WITH  LEFT  VENTRICULAR  ASSISTANT  DEVICE 
,6!$	  IMPLANTATION AS  THE  FIRST PART OF A MULTICENTER 
TRIAL SPONSORED BY $IACRIN )NC IN -ASSACHUSETTS &IVE 
PATIENTS MEDIAN AGE  YEARS	 WITH A HISTORY OF ISCHEMIC 
CARDIOMYOPATHY WERE SELECTED  FOR  THE  STUDY 4HESE PA
TIENTS WERE ON  THE WAITING  LIST  FOR HEART  TRANSPLANTATION 
AND WERE  TO RECEIVE AN ,6!$ IMPLANTATION AS A BRIDGE 
TO TRANSPLANTATION 4HEY WERE ON MAXIMAL INOTROPIC SUP
PORT WITH A MEDIAN ,6%& OF  ! TOTAL OF  X  
CELLS WERE INJECTED INTO EACH PATIENT WITH THE EXCEPTION 
OF ONE PATIENT WHO REQUIRED URGENT ,6!$ IMPLANTATION 
BEFORE SUFFICIENT CELLS COULD BE CULTURED 
$IB ET AL AT THE !RIZONA (EART )NSTITUTE PRESENTED 
A STUDY INVOLVING SKELETAL MYOBLAST TRANSPLANTATION INTO 
THE SCARRED  REGION OF  THE HEART  IN  PATIENTS AS AN AD
JUNCT  TO #!"'  N  	  OR ,6!$  N  	 4HE  STUDY 
WAS PART MULTICENTER INDUSTRYSPONSORED TRIAL FROM $IA
CRIN  AND  INVOLVED  A  DOSEESCALATION  STUDY !UTOLOGOUS 
MYOBLASTS WERE  PURIFIED  AND  PROLIFERATED  IN  VITRO  FROM 
EACH  PATIENTS  THIGH MUSCLE  BIOPSY  SAMPLES !  TOTAL  OF 
  MILLION  TO   MILLION  CELLS  WERE  INJECTED  INTO  THE 
SCAR REGION 4HERE WERE NO INTRAOPERATIVE OR POSTOPERA
TIVE  COMPLICATIONS  RELATED  TO  THE  PROCEDURE  &OLLOWUP 
EVALUATION BY -2) ECHOCARDIOGRAPHY AND 0%4 SHOWED 
SUCCESSFUL  SURVIVAL  OF  THE  TRANSPLANTED  CELLS WITHIN  THE 
HEART AT THE SITE OF GRAFT WHICH REGISTERED IMPROVEMENT 
IN ,6%& FROM  TO  AT  WEEKS FOLLOWUP 
"IOHEART HAS INITIATED THE MULTICENTER &OOD AND $RUG 
!DMINISTRATION  APPROVED -9/(%!24 CLINICAL  TRIAL  TO 
BE  CARRIED  OUT  AT  -OUNT  3INAI  (OSPITAL  .EW  9ORK	 
$UKE 5NIVERSITY AND  THE !MERICAN #ARDIOVASCULAR 2E
SEARCH  )NSTITUTE  !TLANTA	  3IMILARLY  'ENZYME  HAS  AN
NOUNCED  AN  -!')#  MULTICENTER  TRIAL  IN  %UROPE  AND 
!MERICA  3OME  OTHER  INSTITUTE  INVOLVED  IN  MYOBLAST 
TRANSPLANTATION  INCLUDE  THE  5NIVERSITY  OF  #ALIFORNIA  AT 
,OS  !NGELES  4EMPLE  5NIVERSITY  AT  0HILADELPHIA  THE 
5NIVERSITY OF -ICHIGAN AT !NN !RBOR AND THE #LEVELAND 
#LINIC 
/UR GROUP IN 3INGAPORE CARRIED OUT THE FIRST AUTOLOGOUS 
MYOBLAST TRANSPLANTATION ON A BEATING HEART AS A PART OF A 
PHASE  )  CLINICAL  STUDY !  YEAR  OLD  MALE  PATIENT  PRE
SENTED WITH ACUTE MYOCARDIAL INFARCTION 4HE APEX ANTE
RIOR WALL  AND  SEPTUM OF  THE  LEFT VENTRICLE WERE AKINETIC 
AND  THE ,6%& WAS  !FTER  INFORMED CONSENT AND AS 
PART OF AN INSTITUTIONAL REVIEW BOARDCLEARED CLINICAL TRIAL 
THE PATIENT  RECEIVED  X   AUTOLOGOUS MYOBLASTS  AT 
 DIFFERENT SITES IN AND AROUND THE INFARCT REGION DURING 
#!"' 4HE CELLS WERE   PURE FOR DESMIN EXPRESSION 
WITH   VIABILITY AT THE TIME OF INJECTION ! MONTH 
FOLLOWUP REVEALED A PERFUSION DEFECT INVOLVING THE AN
TERIOR  WALL  AND  THE  APEX  WITH  PARTIAL  REVERSIBILITY  ON 
M4CTETRAFOSAMINE NUCLEAR SCAN 4HESE FINDINGS WERE 
IN  AGREEMENT  WITH  PREVIOUSLY  PUBLISHED  REPORTS  AND 
DEMONSTRATED THE SAFETY VIABILITY AND BENEFIT OF AUTOLO
GOUS MYOBLAST TRANSPLANTATION AS AN ADJUNCT TO OFFPUMP 
#!"' !LTHOUGH FURTHER PATIENTS NEED TO BE EVALUATED 
THE  BENEFITS  OF  REDUCED  RISKS  ASSOCIATED WITH  OFFPUMP 
#!"' CARDIOPULMONARY BYPASS OFFER AN ATTRACTIVE TECH
NIQUE FOR DELIVERING THE CELLS FOR TRANSPLANTATION
-ORE RECENTLY :HANG ET AL FROM .ANJING -EDICAL 
5NIVERSITY  0EOPLE 2EPUBLIC  OF #HINA  HAVE  REPORTED  A 
PHASE ) STUDY INCLUDING THREE PATIENTS WITH A HISTORY OF 
CORONARY HEART DISEASE &OUR MILLIMETER OF CELL  SUSPEN
SION DIVIDED  INTO  APPROXIMATELY  DOSES WAS  INJECTED 
INTO THE VENTRICULAR WALL OF THE ISCHEMIC AREA IN LESS THAN 
 MIN !LL  PATIENTS  SURVIVED  THE  PROCEDURE  AND  HAD  AN 
UNEVENTFUL  RECOVERY  4HERE  WERE  REPORTS  OF  OCCASIONAL 
ARRHYTHMIAS (OWEVER  THESE DID NOT  REQUIRE  TREATMENT 
.O  ARRHYTHMIA WAS  OBSERVED  DURING  LONGER  FOLLOWUP 
"ENEFICIAL RESULTS NOTED AT  MONTHS AFTER THE OPERATION 
INCLUDE  AN  INCREASE  IN  LEFT  VENTRICULAR  EJECTION  FRACTION 
AND DECREASED LEFT VENTRICULAR DIASTOLIC DIAMETER AS WELL 
AS  IMPROVED  VENTRICULAR  WALL  THICKNESS  OBSERVED  BY 
D  ECHOCARDIOGRAPHY  4HERE  WAS  SIGNIFICANT  IMPROVE
MENT IN PERFUSION M4C-)")	 AND METABOLIC ACTIVITY 
&DEOXYGLUCOSE	 AT THE CELL IMPLANTATION SITES 

  #IRUGÓA #ARDIOVASCULAR  VOL   .ÞM  
4IME CONSTRAINTS AND THE LOGISTIC PROBLEM OF GENERAT
ING AUTOLOGOUS SKELETAL MYOBLASTS FOR EVERY PATIENT CAN 
BE  OVERCOME  IF  ALLOGENEIC  SKELETAL  MYOBLASTS  FROM 
HEALTHY YOUNG DONORS CAN BE MADE AVAILABLE 4HE SAFETY 
AND  FEASIBILITY  OF  ALLOGENEIC  MYOBLAST  TRANSPLANTATION 
WERE TESTED FOR THE FIRST TIME IN HUMAN SUBJECTS ON *ANU
ARY   AT THE "AKOULEV #ENTER IN -OSCOW 2USSIA 
4WO PATIENTS MEAN AGE 	 RECEIVED BETWEEN  AND  BIL
LION SKELETAL MYOBLASTS AS AN ADJUNCT TO #!"' ON NON
BEATING  HEARTS  4HE  PATIENTS  RECEIVED    MGKGD 
CYCLOSPORINE STARTING  DAYS PRIOR TO UNTIL  MONTHS AFTER 
CELL  TRANSPLANTATION  $ESPITE  CYCLOSPORINE  DISCONTINUA
TION  IMMUNOREJECTION WAS NOT OBSERVED !T  MONTHS 
FOLLOWUP SUBJECTS WERE IN STABLE CONDITION WITH ANGINA 
AT #LASS ))) ##3	 INSTEAD OF #LASS )6 %CHOCARDIOGRA
PHY  DEMONSTRATED    AND    INCREASES  IN  ,6%& 
.UCLEAR IMAGING USING SINGLE PHOTON EMISSION COMPUT
ED TOMOGRAPHY DEMONSTRATED POSITIVE DYNAMICS WITH AN 
INCREASE  IN ,6%& AND A  REDUCTION  IN PERFUSION DEFECTS 
BOTH AT REST AND DURING EXERCISE 4HE RESULTS OF THIS STUDY 
SUPPORT THE CONCEPT OF USING ALLOGENEIC MYOBLASTS AS AN 
ALTERNATIVE  THERAPY  FOR  HEART  FAILURE  USING  ONLY  A  SHORT 
COURSE  MONTHS	 OF IMMUNOSUPPRESSIVE THERAPY 
)-0/24!.4 #/.3)$%2!4)/.3 
#ELL SURVIVAL AND MECHANISM OF 
IMPROVEMENT OF FUNCTION 
-YOBLAST TRANSPLANTATION IS CONFRONTED WITH THE PROB
LEM  OF  DONOR  CELL  SURVIVAL  POSTTRANSPLANTATION  )T  HAS 
BEEN SHOWN  IN ANIMALS  THAT UP  TO  OF GRAFTED CELLS 
DIE WITHIN  THE FIRST   TO  H AFTER  TRANSPLANTATION 
)N ADDITION  TOTAL MYOBLAST  SURVIVAL  IS NOT KNOWN 4HIS 
POOR  CELL  SURVIVAL  HAS  BEEN  ATTRIBUTED  TO  INFLAMMATORY 
CHANGES AT THE SITE OF IMPLANTATION )NFLAMMATION IS THE 
RESULT OF TRAUMA DUE TO NEEDLE PUNCTURE IMMUNEMEDI
ATED REJECTION OF MYOBLASTS OR RELEASE OF IMMUNE MOD
ULATORS AS A RESULT OF MYOBLAST CELL DEATH )N PARTICULAR 
NATURAL  KILLER  CELLS  HAVE  BEEN  SHOWN  TO  PLAY  A  CENTRAL 
ROLE IN THE EARLY DEATH OF GRAFTED MYOBLASTS 4HE EXPO
SURE  OF  MYOBLASTS  TO  THE  CULTURE  MEDIUM  CONTAINING 
ANIMAL PROTEINS IN VITRO MAY LEAD TO CHANGES IN THE SUR
FACE ANTIGEN CHARACTERISTICS OF THE MYOBLASTS AND EXPRES
SION  OF  NEOANTIGENS  4O  OVERCOME  THIS  PROBLEM 
#HACHQUES ET AL ARE USED HUMAN SERUMSUPPLEMENTED 
MYOBLAST CULTURE MEDIUM FOR MYOBLAST PURIFICATION AND 
CULTURE (OWEVER A RECENT INVESTIGATION HAS REVEALED THE 
POOR ABILITY OF HUMAN SERUM SUPPLEMENTED CULTURE ME
DIUM  TO  SUPPORT MYOBLAST  GROWTH  IN  VITRO 4HE  PRES
ENCE OF NONVIABLE CELLS  IN  THE MYOBLAST PREPARATION FOR 
TRANSPLANTATION  RENDERS  THEM VULNERABLE  TO  IMMUNE  RE
JECTION /THER MECHANISMS PROPOSED FOR  LOW CELL SUR
VIVAL  INCLUDE  MECHANICAL  CELL  DAMAGE  DURING  GRAFTING 
AND CELL LEAKAGE FROM THE SITES OF NEEDLE PUNCTURE 
(ISTOLOGICAL  DATA  OF  THE GRAFTED  AREAS  IN  THE HUMAN 
PATIENTS HAVE BEEN REPORTED BY (AGEGE ET AL AND 0A
GANI 4HE PATIENT OF -ENASCHÏS  LANDMARK STUDY DIED 
  MONTHS  AFTER  RECEIVING  MYOBLAST  TRANSPLANTATION 
4HE HEART WAS EXPLANTED POST MORTEM AND SUBJECTED  TO 
HISTOLOGICAL  STUDIES 4HE  RESULTS  SHOWED  THE  PRESENCE 
OF  MYOFIBRILS  THAT  STAINED  FOR  SKELETAL  MUSCLESPECIFIC 
MYOSIN  HEAVY  CHAIN  IN  THE  INJECTED  AREAS  4HEY  WERE 
SEEN  TO  BE  ALIGNED  IN  A  DIRECTION  PARALLEL  TO  HOST MYO
CARDIAL FIBERS 3LOWTWITCH ISOFORMS AND FASTTWITCH ISO
FORMS AS WELL AS COEXPRESSION OF BOTH FORMS WERE SEEN 
IN PERCENTAGES OF   AND  RESPECTIVELY 0ERCENT
AGES  OF      AND    ARE  SEEN  IN  HUMAN  SKELETAL 
MUSCLE 4HIS SWITCH OF PHENOTYPE TOWARD THE SLOWTWITCH 
ISOFORM IS THOUGHT TO BE CAUSED BY REPEATED STRETCH AS A 
RESULT OF CONTRACTION OF  THE ADJACENT MYOCARDIUM OR BY 
INCOMPLETE ELIMINATION OF THE FIBERS EXPRESSING ONLY THE 
FAST ISOFORM #OMPARED TO NO INJECTED AREAS AREAS WHERE 
MYOBLASTS WERE INJECTED SHOWED A SIGNIFICANT INCREASE 
IN NUMBER OF BLOOD VESSELS  F  CELLS VS  F  
CELLS P  	 -ULTINUCLEATED GIANT CELLS HAVE ALSO 
BEEN SEEN IN GRAFTED SEGMENTS IN THE MYOCARDIUM AS
SOCIATED  WITH  NONCELLULAR  MATERIAL  INTRODUCED  DURING 
TRANSPLANTATION !SIDE FROM THESE CELLS NO SIGN OF ON
GOING INFLAMMATION WAS REPORTED 4HERE WAS AN ABSENCE 
OF CONNEXIN STAINING ON IMMUNOHISTOCHEMISTRY THUS 
SUGGESTING  IMPAIRED  ELECTROPHYSIOLOGICAL  COUPLING  BE
TWEEN THE GRAFTED CELLS AND THE SURROUNDING HOST CARDIO
MYOCYTES 
4HE SAFETY AND FEASIBILITY OF CELL TRANSPLANTATION HAVE 
BEEN REPEATEDLY DOCUMENTED DURING MULTIPLE PRECLINICAL 
ANIMAL  EXPERIMENTS  AND  CLINICAL  PHASE  )  STUDIES  4HE 
ONLY  SERIOUS POSTOPERATIVE  ADVERSE  EVENT  RELATED  TO  THE 
PROCEDURE  WAS  THE  OCCURRENCE  OF  VENTRICULAR  ARRHYTH
MIAS 
#ARDIAC ARRHYTHMIA AS  A POSTOPERATIVE COMPLICATION 
HAS  BEEN  REPORTED  AFTER  MYOBLAST  TRANSPLANTATION  -E
NASCHÏ REPORTED  THAT  OF  THE  PATIENTS SUFFERED FROM 
SUSTAINED  MONOMORPHIC  VENTRICULAR  TACHYCARDIA  64	 
THAT WAS RESISTANT TO TREATMENT BY AMIODARONE AND BETA
BLOCKERS  AND  NECESSITATED  THE  IMPLANTATION  OF  AN  AUTO
MATIC  INTERNAL  CARDIOVERTERDEFIBRILLATOR  0AGANI  REPORTS 
THAT  OF  PATIENTS SUFFERED FROM ATRIAL FIBRILLATION N  	 
OR  VENTRICULAR  TACHYCARDIA  N    	  4HE  PATIENT  IN  THE 
0OLAND TRIAL ALSO SUFFERED FROM AN EPISODESUSTAINED VEN
TRICULAR TACHYCARDIA THAT WAS RESOLVED BY TREATMENT WITH 
AMIODARONE  3IX  OF  EIGHT  PATIENTS  WHO  DEVELOPED  AR
RHYTHMIAS HAD A PRIOR HISTORY OF ARRHYTHMIAS -OST EPI
SODES OF ARRHYTHMIAS WERE CLINICALLY WELL  TOLERATED AND 
DID NOT RESULT IN ANY DEATHS 4HE ETIOLOGY OF ARRHYTHMIA 

  %UGENE +7 3IM ET AL -YOBLAST TRANSPLANTATION FOR HEART FAILURE n &ROM BENCH TO BEDSIDE

AFTER MYOBLAST TRANSPLANTATION IS PROBABLY MULTIFACTORIAL 
AND INCLUDES AN INHOMOGENEOUS DISTRIBUTION OF GAP JUNC
TIONS  A  DIFFERENCE  IN  THE  ISOTYPES  OF  ION  CHANNELS  ON 
SKELETAL MUSCLE  CELLS  AND CARDIOMYOCYTES  AND  THE  RE
LEASE OF INFLAMMATORY MEDIATORS AFTER NEEDLE PUNCTURE 
4HE PRESENCE OF A NONMYOGENIC POPULATION PRESENT IN THE 
MYOBLAST CELL POPULATION  THAT  IS  TRANSPLANTED MAY FUR
THER AGGRAVATE THE SITUATION &URTHER MORE THE COMPLICA
TION OF ARRHYTHMIAS WAS NOT CONSISTENT AND OTHER STUDIES 
DID NOT SEEM TO HAVE THE SAME PROBLEMS 
/N  THE  OTHER  HAND  THE  ENDPOINT  MEASUREMENTS  IN 
THESE  STUDIES  HIGHLIGHT  IMPROVEMENT  IN  THE  QUALITY  OF 
LIFE  REDUCED NITROGLYCERINE CONSUMPTION ENHANCED EX
ERCISE TOLERANCE IMPROVEMENT IN .9(! #LASS IMPROVE
MENT  IN  WALL  MOTION  BY  ECHOCARDIOGRAPHY  AND 
SIGNIFICANTLY REDUCED PERFUSION DEFECTS 
&5452% $)2%#4)/.3 
4HE  RESULTS OF PHASE  ) HUMAN STUDIES  ALTHOUGH EN
COURAGING ARE STILL PRELIMINARY ! MORE CONCERTED COL
LABORATIVE  EFFORT  BETWEEN  THE  VARIOUS  RESEARCH  GROUPS 
INVOLVED IS LIKELY TO FURTHER THE KNOWLEDGE IN THIS FIELD 
4HE DEVELOPMENT OF STRICT  INCLUSION AND EXCLUSION CRI
TERIA  BETTER  ESTABLISHMENT  OF  THE  TARGET  POPULATION  OF 
PATIENTS WHO MAY BENEFIT FROM CELL TRANSPLANTATION AND 
MORE WIDESPREAD TRIALS WILL ALLOW THE REAL BENEFIT OF THIS 
CONCEPT  TO  BE  ESTABLISHED  4HE  METHODS  FOR  ENDPOINT 
MEASUREMENTS OF THE STUDIES SHOULD BE MADE MORE UNI
FORM SO THAT THE RESULTS EMANATING FROM VARIOUS CENTRES 
MAY BE MORE UNIFORMLY INTERPRETED 4O DATE STUDIES ON 
MYOBLAST  TRANSPLANTATION  HAVE  BEEN  CARRIED  OUT  AS  AN 
ADJUNCT  TO  ROUTINE  SURGICAL  PROCEDURES  SUCH  AS  #!"' 
AND MECHANICALASSIST DEVICE IMPLANTATION 4HIS MAKES 
IT HARD TO REALIZE THE TRUE EFFECTIVENESS OF THE CELL TRANS
PLANTATION  APPROACH  4HE  BENEFICIAL  EFFECTS  COULD  BE 
RELATED  DIRECTLY  TO  THE  INJECTED  CELLS  OR  INDIRECTLY  TO  A 
COMBINED EFFECT OF SURGICAL MANIPULATION AND CELL TRANS
PLANTATION &URTHER INVESTIGATIVE WORK NEEDS TO BE DONE 
ON THE BASIC ISSUES SUCH AS THE IDEAL CELL TYPE THE OPTI
MAL  NUMBER  OF  CELLS  AND  THE  ROUTE  OF  ADMINISTRATION 
4HE  BENEFICIAL  EFFECTS  SEEN  TO  DATE MAY  BE  RELATED  DI
RECTLY  TO  THE  INJECTED  CELLS  OR  MEDIATED  INDIRECTLY  BY 
ANGIOGENIC OR GROWTH FACTORS SECRETED BY THE TRANSPLANT
ED CELLS 4HE MOST SUITABLE TIME FOR CELL TRANSPLANTATION 
AFTER ISCHEMIC INJURY HAS ALSO NOT BEEN RESOLVED )F CELLS 
ARE TRANSPLANTED TOO EARLY AFTER THE INJURY THEIR SURVIVAL 
COULD  BE  IMPAIRED  BY  THE  ONGOING  INFLAMMATORY  RE
SPONSE AT  THE  INJURED SITE  IF  THEY ARE  INJECTED  TOO  LATE 
TRANSPLANTATION  MAY  NOT  SUCCESSFULLY  PREVENT  FIBROSIS 
FROM  DEVELOPING  IN  THE  INJURED  REGION  4HE  OPTIMAL 
MODE OF CELL DELIVERY CONTINUES TO BE EVALUATED 7ITH
OUT  EXCEPTION  IN  ALL  THE  PREVIOUS  CLINICAL  STUDIES  RE
PORTED  DIRECT  INTRAMYOCARDIAL  INJECTION  HAS  BEEN  USED 
FOR MYOBLAST DELIVERY 4HIS IS THE SIMPLEST APPROACH BUT 
IS  TOO  INVASIVE  IF  CONSIDERED  IN  THE  PERSPECTIVE  OF  THE 
CLINICAL  SCENARIO  IN WHICH CELL  THERAPY WILL BE USED AS 
THE SOLE THERAPY &URTHERMORE LOSS OF CELLS DUE TO LEAK
AGE FROM THE SITE OF INJECTION AFTER DIRECT INJECTION NEEDS 
TO  BE  PREVENTED  )N  ADDITION  TO  THE  SURGICAL  ROUTE  OF 
DIRECT INTRAMYOCARDIAL CELL TRANSPLANTATION INTRAVENOUS 
INTRACORONARY INTRAARTERIAL AND CATHETERBASED DELIVERY 
SYSTEMS  ARE  CURRENTLY  BEING  INTENSIVELY  EVALUATED  AS 
ALTERNATIVE APPROACHES FOR CELL DELIVERY 4HE RESULTS 
IN  THE  ANIMAL  STUDIES HAVE  SHOWN  THE  FEASIBILITY OF  AN 
ENDOVASCULAR  ROUTE  OF  DELIVERY  TO  AN  INFARCTED  AREA 
#ELLS CAN BE DELIVERED ACCURATELY WITH THE ASSISTANCE OF 
./'!  ELECTROMECHANICAL  MAPPING  #ATHETERBASED 
NEEDLE  ENDOMYOCARDIAL  INJECTION  IS  ASSOCIATED  WITH 
EQUIVALENT OR SUPERIOR INJECTATE RETENTION COMPARED WITH 
OPEN CHEST EPICARDIAL  INJECTION 4HE PERCUTANEOUS PRO
CEDURE RAISES THE POSSIBILITY OF REPEATED GRAFTING OF CELLS 
WITHOUT  THE NEED  TO  PERFORM AN OPEN  CHEST  PROCEDURE 
4HE USE OF MYOBLASTS FROM OTHER THAN AUTOLOGOUS SOURC
ES MAY RESULT IN ONTHESHELF AVAILABILITY OF CELLS WHICH 
WILL  HELP  SOLVE  SOME  OF  THE  LOGISTIC  PROBLEMS  4HE 
MECHANISMS RESPONSIBLE FOR  THE BENEFICIAL EFFECTS SEEN 
WITH CELL TRANSPLANTATION REMAIN CONTROVERSIAL %LUCIDA
TION  OF  THE  EXACT  MECHANISM  OF  CELL  SURVIVAL  AND  EX
ACTLY  HOW  THE  TRANSPLANTED  CELLS  CONTRIBUTE  TO 
IMPROVEMENT IN OVERALL CARDIAC FUNCTION REMAIN THE FO
CUS  OF  INTENSE  INVESTIGATION  )N  ADDITION  THE  SPECTRUM 
OF  CARDIOVASCULAR  PATHOLOGIES  THAT  COULD  BENEFIT  FROM 
MYOBLAST TRANSPLANTATION NEEDS TO BE ASSESSED #LINICAL 
TRIALS  MUST  BE  DESIGNED  TO  ADDRESS  THESE  BASIC  ISSUES 
&URTHER TO THIS THERE IS A NEED FOR BLINDED AND PLACEBO
CONTROLLED  STUDIES  TO  ASSESS  THE  TRUE  EFFICACY  OF  THIS 
APPROACH 4HERE  IS MUCH  THEORETICAL  AND  PRACTICAL  AD
VANTAGE  TO  COMBINING  ANGIOGENIC  GENE  THERAPY  WITH 
MYOBLAST TRANSPLANTATION USING MYOBLASTS AS CARRIERS OF 
THE EXOGENOUS GENES ENCODING ONE OR MORE ANGIOGENIC 
FACTORS )N CONCLUSION THE USE OF NOVEL CELLBASED TECH
NIQUES  TO  ASSIST WITH  CARDIAC  REGENERATION  HOLDS MUCH 
PROMISE  FOR  THE  TREATMENT  OF  HEART  FAILURE  AND  COULD 
COMPLEMENT OTHER AVAILABLE THERAPIES 
2%&%2%.#%3 
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